SYNTHORX, INC.

THOR NASDAQ
15.80
-1.20
-7.06%
Closed 16:00 07/23 EDT
Open
17.00
Prev Close
17.00
High
17.07
Low
15.55
Volume
234.85K
Avg Vol (3M)
73.71K
52 Week High
23.53
52 Week Low
11.00
% Turnover
0.86%
Market Cap
433.20M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers SYNTHORX, INC. THOR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.
MORE >

Recently

Name
Price
%Change